Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256797 · ClinicalTrials.gov registry record
Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 353,980
- Enrollment target
NCT05256797 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 353,980 participants.
The verdict
NCT05256797 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 353,980 participants
- Enrollment target
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Interventions
- DRUG Apixaban
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353,980 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2022-06-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256797
The ClinicalTrials.gov registry entry for NCT05256797 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 353,980 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT05256797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05256797 about?
NCT05256797 is a clinical study titled "Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data". Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such...
What is the current status of trial NCT05256797?
This trial is currently completed. The enrollment target is 353,980 participants. The study started on 2021-05-03. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT05256797?
The interventions under investigation include: Apixaban (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT05256797?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.